Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

BACKGROUND: Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared to be independent of the phosphoinos...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Sacha J, Casbard, Angela, Carucci, Margherita, Ingarfield, Kate, Butler, Rachel, Morgan, Sian, Meissner, Magdalena, Bale, Catherine, Bezecny, Pavel, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, de Bruin, Elza C, Schiavon, Gaia, Foxley, Andrew, Jones, Robert H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630162/
https://www.ncbi.nlm.nih.gov/pubmed/35671774
http://dx.doi.org/10.1016/S1470-2045(22)00284-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630162/
https://www.ncbi.nlm.nih.gov/pubmed/35671774
http://dx.doi.org/10.1016/S1470-2045(22)00284-4

Ejemplares similares